Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 20/20 | 0.84 |
| ▸ | KDR | P35968 | 4/20 | 0.84 |
| ▸ | KIT | P10721 | 2/20 | 0.84 |
| ▸ | GAK | O14976 | 1/20 | 0.82 |
| ▸ | ACOX3 | O15254 | 1/20 | 0.82 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.82 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.82 |
| ▸ | EGFR | P00533 | 1/20 | 0.82 |
| ▸ | ESR1 | P03372 | 1/20 | 0.82 |
| ▸ | PGR | P06401 | 1/20 | 0.82 |
| ▸ | RET | P07949 | 1/20 | 0.82 |
| ▸ | ROS1 | P08922 | 1/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.82 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.82 |
| ▸ | FER | P16591 | 1/20 | 0.82 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.82 |
| ▸ | PDE4A | P27815 | 1/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895699 | 1.00 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL29895704 | 1.00 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL29895703 | 1.00 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897049 | 0.94 | ALK (0.87) | ALKKDRKITGAKACOX3 | |
| SCHEMBL896916 | 0.93 | ALK (0.88) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897496 | 0.92 | ALK (0.79) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897477 | 0.91 | ALK (1.00) | ALKKDRKITGAKACOX3 | |
| SCHEMBL897175 | 0.91 | ALK (0.94) | ALKKDRKIT | |
| SCHEMBL897455 | 0.91 | ALK (0.84) | ALKKDRKITGAKACOX3 | |
| SCHEMBL896333 | 0.91 | ALK (1.00) | ALKKDRKITGAKACOX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-04-10 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-14 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-110891947-B | Process for preparing ailutinib or a pharmaceutically acceptable salt thereof | 北京费森尤斯卡比医药有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-11465999-B2 | Process for preparing Alectinib or a pharmaceutically acceptable salt thereof | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2022-10-11 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2022-09-29 | — | — | US | disclosed |
| US-9126931-B2 | Tetracyclic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-09-08 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-06-04 | — | — | US | disclosed |
| EP-2606886-A1 | COMPOSITION CONTAINING TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-2606886-A1 | COMPOSITION CONTAINING TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-06-06 | — | — | US | disclosed |
| EP-2441753-A1 | TETRACYCLIC COMPOUND | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143877-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885KDR 71/4885KIT 250/4885 |
| US-20230142119-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885KIT 378/4885 |
| US-20250114327-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885KDR 71/4885KIT 250/4885 |
| US-20120083488-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885KIT 378/4885 |
| US-20220306578-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885KIT 378/4885 |
| US-20230398096-A1 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | ALK, ALPI, TTR | ALK 1/4885KDR 71/4885KIT 250/4885 |
| US-11465999-B2 | Process for preparing Alectinib or a pharmaceutically acceptable salt thereof | PLEC, SF3B5, FCGR3B | ALK 78/4885KDR 1642/4885KIT 652/4885 |
| US-20150150845-A1 | TETRACYCLIC COMPOUND | ALK, TTR, ACVR1 | ALK 1/4885KDR 167/4885KIT 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.